Vaxart (NASDAQ:VXRT – Get Rating) announced its earnings results on Monday. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04), MarketWatch Earnings reports. Vaxart had a negative net margin of 7,900.22% and a negative return on equity of 36.68%.
VXRT opened at $3.16 on Tuesday. The firm has a market cap of $399.44 million, a P/E ratio of -5.45 and a beta of 0.67. Vaxart has a 1-year low of $3.11 and a 1-year high of $10.33. The company has a 50 day simple moving average of $4.54 and a two-hundred day simple moving average of $5.53.
Separately, Zacks Investment Research raised shares of Vaxart from a “sell” rating to a “hold” rating in a report on Thursday, May 5th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Vaxart currently has a consensus rating of “Buy” and an average price target of $12.10.
Vaxart Company Profile (Get Rating)
Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection.
- Get a free copy of the StockNews.com research report on Vaxart (VXRT)
- Shopify (NYSE: SHOP) Approaches Key Support Level
- The Low In Lordstown Motors May Not Be The Last
- Follow The Money To Cigna
- Intuitive Surgical is an Intuitive Buy
- MarketBeat Podcast: Barbell Strategy To Strengthen Your Portfolio
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.